Table 3.

Multivariable analysis of TSF and OS between TBP pts and non-TBP pts.

	TSF	OS
	HR (95% CI); p value
TBP pts vs non-TBP pts	0.46 (0.36-0.59); p < 0.001	0.54 (0.40-0.72); p < 0.001
Age	0.99 (0.99-1.00); p = 0.088	1.00 (0.99-1.01); p = 0.70
Gender (Female vs Male)	1.16 (0.95-1.43); p = 0.14	1.23 (0.98-1.55); p = 0.072
MSKCC score
1	1.00 (ref)	1.00 (ref)
2	1.40 (0.98-1.99); p = 0.064	1.33 (0.88-2.00); p = 0.18
3	1.80 (1.10-2.94); p = 0.019	1.77 (1.04-3.03); p = 0.036
Meet-URO score
1	1.00 (ref)	1.00 (ref)
2	1.13 (0.77-1.66); p = 0.54	1.47 (0.92-2.37); p = 0.11
3	1.17 (0.74-1.84); p = 0.50	1.83 (1.06-3.14); p = 0.029
4	1.54 (0.94-2.51); p = 0.086	3.05 (1.73-5.40); p < 0.001
5	4.07 (2.22-7.47); p < 0.001	6.35 (3.24-12.46); p < 0.001
Lymphnode metastases	0.93 (0.78-1.12); p = 0.47	1.09 (0.89-1.34); p = 0.40
Visceral metastases	1.01 (0.75-1.36); p = 0.94	0.99 (0.72-1.37); p = 0.95

Pts, patients; TBP, treatment beyond progression; TSF, time to strategy failure; OS, overall survival; MSKCC, Memorial Sloan–Kettering Cancer Center; HR, hazard ratio; CI, confident interval.